Fig. 5

HBD2 involved deeply in the anti-tumor mechanism of Anisomycin in treatment of cervical cancer. (A) SiHa cells were exposed to varying concentrations of Anisomycin from 0, 0.25, 0.5, 0.75 to 1 µM for 24 h, and the levels of p-p38 and GAPDH proteins were assessed using Western blot analysis. The relative expression of these proteins was quantified using Image J software, with GAPDH serving as an internal control. SiHa, CaSki and C33Acells were treated with different concentrations of Anisomycin for 24 h, and HBD2 mRNA levels (B) and cell viability (C) were measured using RT-qPCR and CCK8 assay, respectively.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, vs. 0 µM group; (D) and (E) Apoptosis in SiHa and C33A cells treated with various concentrations of Anisomycin for 24 h was evaluated using flow cytometry. ***P < 0.001, ****P < 0.0001, vs. DMSO group